Krishna R - Search Results

1

Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry.

Stone JA, Banfield C, Pfister M, Tannenbaum S, Allerheiligen S, Wetherington JD, Krishna R, Grasela DM. Stone JA, et al. Among authors: krishna r. J Clin Pharmacol. 2010 Sep;50(9 Suppl):20S-30S. doi: 10.1177/0091270010377628. J Clin Pharmacol. 2010. PMID: 20881214

2

Effective integration of systems biology, biomarkers, biosimulation, and modeling in streamlining drug development.

Krishna R, Schaefer HG, Bjerrum OJ. Krishna R, et al. J Clin Pharmacol. 2007 Jun;47(6):738-43. doi: 10.1177/0091270007300746. Epub 2007 Apr 26. J Clin Pharmacol. 2007. PMID: 17463216 No abstract available.

3

Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.

Bergman A, Mistry GC, Luo WL, Liu Q, Stone J, Wang A, Zeng W, Chen L, Dilzer S, Lasseter K, Herman GA, Wagner JA, Krishna R. Bergman A, et al. Among authors: krishna r. Biopharm Drug Dispos. 2007 Sep;28(6):307-13. doi: 10.1002/bdd.559. Biopharm Drug Dispos. 2007. PMID: 17571284 Clinical Trial.

4

Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.

Bergman A, Ebel D, Liu F, Stone J, Wang A, Zeng W, Chen L, Dilzer S, Lasseter K, Herman G, Wagner J, Krishna R. Bergman A, et al. Among authors: krishna r. Biopharm Drug Dispos. 2007 Sep;28(6):315-22. doi: 10.1002/bdd.560. Biopharm Drug Dispos. 2007. PMID: 17575559 Clinical Trial.

5

Model-based benefit-risk assessment: can Archimedes help?

Krishna R. Krishna R. Clin Pharmacol Ther. 2009 Mar;85(3):239-40. doi: 10.1038/clpt.2008.240. Clin Pharmacol Ther. 2009. PMID: 19223878 Review.

6

Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development.

Wetherington JD, Pfister M, Banfield C, Stone JA, Krishna R, Allerheiligen S, Grasela DM. Wetherington JD, et al. Among authors: krishna r. J Clin Pharmacol. 2010 Sep;50(9 Suppl):31S-46S. doi: 10.1177/0091270010377629. J Clin Pharmacol. 2010. PMID: 20881215

7

The Emerging Role of Digital Technologies in Early Clinical Development.

Krishna R. Krishna R. Clin Pharmacol Ther. 2018 Jan;103(1):39-41. doi: 10.1002/cpt.906. Epub 2017 Nov 6. Clin Pharmacol Ther. 2018. PMID: 29105745

8

Effective integration of systems biology, biomarkers, biosimulation and modelling in streamlining drug development.

Krishna R, Schaefer HG, Bjerrum OJ. Krishna R, et al. Eur J Pharm Sci. 2007 May;31(1):62-7. doi: 10.1016/j.ejps.2007.02.003. Epub 2007 Feb 20. Eur J Pharm Sci. 2007. PMID: 17408933

9

The clinical utility index as a practical multiattribute approach to drug development decisions.

Poland B, Hodge FL, Khan A, Clemen RT, Wagner JA, Dykstra K, Krishna R. Poland B, et al. Among authors: krishna r. Clin Pharmacol Ther. 2009 Jul;86(1):105-8. doi: 10.1038/clpt.2009.71. Epub 2009 May 20. Clin Pharmacol Ther. 2009. PMID: 19458614

10

A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects.

Bloomfield DM, Krishna R, Hreniuk D, Hickey L, Ghosh K, Bergman AJ, Miller J, Gutierrez MJ, Stoltz R, Gottesdiener KM, Herman GA, Wagner JA. Bloomfield DM, et al. Among authors: krishna r. J Clin Pharmacol. 2009 Aug;49(8):937-46. doi: 10.1177/0091270009337511. J Clin Pharmacol. 2009. PMID: 19602719 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

692 results

Search Page

Filters